Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip; Nasser K. Altorki; Caicun Zhou; Tibor Csőszi; Ihor Vynnychenko; Oleksandr Goloborodko; Alexander Luft; А. Л. Акопов; Alex Martínez‐Martí; Hirotsugu Kenmotsu; Yuh‐Min Chen; Antonio Chella; Shunichi Sugawara; David Voong; Fan Wu; Jing Yi; Yu Deng; Mark L. McCleland; Elizabeth Bennett; Barbara J. Gitlitz; Heather A. Wakelee

doi:10.1016/s0140-6736(21)02098-5

Keywords

AtezolizumabMedicineAdjuvantOncologyAdjuvant chemotherapyStage (stratigraphy)Lung cancerInternal medicineChemotherapyOpen labelCancerClinical trialImmunotherapyBreast cancerPembrolizumab

Affiliated Institutions

Related Publications

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platin...

2019 Journal of Clinical Oncology 1616 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn , Masafumi Ikeda , Andrew X. Zhu +17 more

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death r...

2020 Journal of Clinical Oncology 1120 citations

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid , Hope S. Rugo , Sylvia Adams +12 more

2019 The Lancet Oncology 1134 citations

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer , Fabrice Barlési , Daniel Waterkamp +22 more

2016 The Lancet 4635 citations

Publication Info

Year: 2021
Type: article
Volume: 398
Issue: 10308
Pages: 1344-1357
Citations: 1356
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1356

OpenAlex

Cite This

APA Style

                            
                                
                                    Enriqueta Felip, 
                                
                                    Nasser K. Altorki, 
                                
                                    Caicun Zhou
                                
                                et al.
                            
                            (2021). 
                            Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. 
                            The Lancet
                            , 398
                            (10308)
                            , 1344-1357.
                            https://doi.org/10.1016/s0140-6736(21)02098-5
                        

Identifiers

DOI: 10.1016/s0140-6736(21)02098-5